BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20177061)

  • 1. A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.
    Nieves EC; Manchanda N
    J Biol Chem; 2010 Apr; 285(17):12595-603. PubMed ID: 20177061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and in vitro expression of the plasminogen activators and urokinase type plasminogen activator receptor (u-PAR) in the pig oviduct.
    Roldán-Olarte M; García DC; Jiménez-Díaz M; Valdecantos PA; Miceli DC
    Anim Reprod Sci; 2012 Dec; 136(1-2):90-9. PubMed ID: 23103014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell invasion is affected by differential expression of the urokinase plasminogen activator/urokinase plasminogen activator receptor system in muscle satellite cells from normal and dystrophic patients.
    Fibbi G; Barletta E; Dini G; Del Rosso A; Pucci M; Cerletti M; Del Rosso M
    Lab Invest; 2001 Jan; 81(1):27-39. PubMed ID: 11204271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells.
    Oszajca K; Bieniasz M; Brown G; Swiatkowska M; Bartkowiak J; Szemraj J
    Biochem Cell Biol; 2008 Dec; 86(6):477-86. PubMed ID: 19088796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-1beta regulates urokinase plasminogen activator (u-PA), u-PA receptor, soluble u-PA receptor, and plasminogen activator inhibitor-1 messenger ribonucleic acid expression in cultured human endometrial stromal cells.
    Chung HW; Wen Y; Ahn JJ; Moon HS; Polan ML
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1332-40. PubMed ID: 11238529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
    Guiducci S; Del Rosso A; Cinelli M; Perfetto F; Livi R; Rossi A; Gabrielli A; Giacomelli R; Iori N; Fibbi G; Del Rosso M; Cerinic MM
    Arthritis Res Ther; 2005; 7(6):R1244-53. PubMed ID: 16277677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
    Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
    J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-chain urokinase, receptor, and type 1 inhibitor in cultured human mesangial cells.
    Glass WF; Kreisberg JI; Troyer DA
    Am J Physiol; 1993 Mar; 264(3 Pt 2):F532-9. PubMed ID: 8384415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system.
    Michaud-Levesque J; Rolland Y; Demeule M; Bertrand Y; Béliveau R
    Biochim Biophys Acta; 2005 Apr; 1743(3):243-53. PubMed ID: 15843038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.
    Reuning U; Bang NU
    Arterioscler Thromb; 1992 Oct; 12(10):1161-70. PubMed ID: 1327097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T; Toet K; Quax P; Kooistra T
    Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system.
    Killeen SD; Wang JH; Andrews EJ; Redmond HP
    Br J Cancer; 2009 May; 100(10):1589-602. PubMed ID: 19436306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
    J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin decreases the urokinase receptor and surface-localized fibrinolysis in cultured endothelial cells.
    Li XN; Varma VK; Parks JM; Benza RL; Koons JC; Grammer JR; Grenett H; Tabengwa EM; Booyse FM
    Arterioscler Thromb Vasc Biol; 1995 Mar; 15(3):410-9. PubMed ID: 7749851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor regulates cell surface plasminogen activator activity on human trophoblast cells.
    Zhang JC; Sakthivel R; Kniss D; Graham CH; Strickland DK; McCrae KR
    J Biol Chem; 1998 Nov; 273(48):32273-80. PubMed ID: 9822706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.